Sansure Biotech Inc. (SHA:688289)

China flag China · Delayed Price · Currency is CNY
17.42
+0.18 (1.04%)
Apr 29, 2026, 3:00 PM CST
-7.24%
Market Cap 9.90B
Revenue (ttm) 1.65B
Net Income (ttm) 198.15M
Shares Out 574.18M
EPS (ttm) 0.34
PE Ratio 50.71
Forward PE 26.94
Dividend 0.54 (3.13%)
Ex-Dividend Date n/a
Volume 2,622,493
Average Volume 3,407,127
Open 17.31
Previous Close 17.24
Day's Range 17.24 - 17.43
52-Week Range 17.07 - 23.45
Beta 0.66
RSI 38.87
Earnings Date Apr 30, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an... [Read more]

Sector Healthcare
Founded 2008
Employees 2,409
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688289
Full Company Profile

Financial Performance

In 2025, Sansure Biotech's revenue was 1.65 billion, an increase of 13.04% compared to the previous year's 1.46 billion. Earnings were 198.15 million, a decrease of -28.10%.

Financial Statements

News

There is no news available yet.